Hawaii News

Centers for Disease Control and Prevention updates RSV vaccine recommendation for adults

Play
Listen to this Article
1 minute
Loading Audio... Article will play after ad...
Playing in :00
A
A
A

A patient receives a vaccine. Photo Courtesy: Gustavo Fring, Pexels

The federal Centers for Disease Control and Prevention on Wednesday updated its recommendation for the use of respiratory syncytial virus vaccines in people ages 60 and older.

For this upcoming respiratory virus season, CDC recommends:

  • Everyone ages 75 and older receive the RSV vaccine.
  • People ages 60-74 who are at increased risk of severe RSV, meaning they have certain chronic medical conditions, such as lung or heart disease, or they live in nursing homes, receive the RSV vaccine.

“The CDC has updated its RSV vaccination recommendation for older adults to prioritize those at highest risk for serious illness from RSV,” said CDC Director Dr. Mandy Cohen. “People 75 or older, or between 60-74 with certain chronic health conditions or living in a nursing home should get one dose of the RSV vaccine to provide an extra layer of protection.”

ARTICLE CONTINUES BELOW AD
ARTICLE CONTINUES BELOW AD

This recommendation is for adults who did not get an RSV vaccine last year. The RSV vaccine is not currently an annual vaccine, meaning people do not need to get a dose every RSV season. Eligible adults can get an RSV vaccine at any time, but the best time to get vaccinated is in late summer and early fall before RSV usually starts to spread in communities.

Wednesday’s updated recommendation for people 60 and older replaces the recommendation made last year to simplify RSV vaccine decision-making for clinicians and the public.

Immunizations were available last year for the first time to protect people at increased risk for severe RSV, including infants and young children, and people ages 60 and older. Wednesday’s updated recommendation is based on analyses of RSV disease burden among people 60 and older, as well as RSV vaccine effectiveness and cost-effectiveness studies. Those studies included the first real-world data since RSV vaccines were recommended for people 60 and older.

ADVERTISEMENT

Sponsored Content

Subscribe to our Newsletter

Stay in-the-know with daily
headlines delivered straight to your inbox.
Cancel
×

Comments

This comments section is a public community forum for the purpose of free expression. Although Kauai Now encourages respectful communication only, some content may be considered offensive. Please view at your own discretion. View Comments